European Generic Drug Markets - Growth to 2007

The generic drug sector in Europe is poised for significant market growth over the next 5 years. Already generics account for 50% of all prescriptions and this is forecast to reach 75% by 2007.

Cost-containment pressures on healthcare services and organisations will lead to increased adoption of generic substitution and prescribing practices in many EU Member States boosting volume and value for the industry. Other factors such as patent expiry of leading drugs and EU enlargement are intrinsic in the growth and expansion of the EU generics sector to 2007.

European government initiatives to reduce pharmaceutical budgets will become increasing evident over the next decade. Specific decree laws and reforms will continue to effect changes in pricing and reimbursement, encouraging the use of generics.

Countries such as Germany and the UK continue to dominate the European generics sector, but Southern Mediterranean countries such as Spain and Italy who have had low value and volume generic markets are forecast to increase rapidly mainly as a result of government cost-containment pressures. The Dutch and Scandinavian markets are also expected to show sustained growth in line with growth of total markets and positive disposition towards generics.

European Generic Drug Markets; Growth to 2007, a new 50,000 word market report from Urch Publishing, provides the valuable market data and insight that both ethical and generic pharmaceutical companies will find useful in their business.

The report answers questions vital to your business:

• What are key factors driving growth in the European generics market?
• What is the current regulatory and legislative framework for generics in Europe?
• Which factors are shaping the future of generic markets?
• What are the market opportunities for generics to 2007?
• Which countries are earmarked for high growth in generics?
• How will recent EC regulatory proposals affect generics in the EU? ? What are the European country-specific market valuations of generics to 2007?
• What are the strategies of multinationals to protect patented drugs?
• What are the strategies employed by generics companies to grow and sustain their industry?

Six reasons why you and your company should invest in this report.

1. Provides comprehensive insight into the European generics industry

2. Gives a strategic overview of the dynamics of the generics sector

3. Indicates trends and opportunities in the generics sector in Europe

4. Discusses recent legislative and regulatory changes in the EU

5. Details market values for generics in 14 territories, including EU accession countries

6. Over 50 useful figures and tables

Who should invest in this report?

• CEOs
• Business Development Executives/Strategists
• Senior Executives
• Generic firms
• Multinationals with patent expiries approaching
• Pharmaceutical organisations
• Regulatory officials
• Government and trade libraries
• Market Research Analysts

The Author

Timothy Atkinson Bsc. (Hons.) has worked for over ten years in medical and scientific publishing environments. He has previously managed numerous medical communication projects customised for the pharmaceutical industry and is a member of the European Medical Writers Association. Over the past five years, Tim has authored over 20 pharmaceutical management reports, trade articles, and press features and has worked for many leading pharmaceutical firms and healthcare organisations.